Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by American Century Companies Inc.

American Century Companies Inc. increased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 14.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 605,267 shares of the company's stock after buying an additional 76,262 shares during the quarter. American Century Companies Inc. owned about 0.49% of Vaxcyte worth $49,547,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Teacher Retirement System of Texas boosted its position in Vaxcyte by 42.1% in the 4th quarter. Teacher Retirement System of Texas now owns 32,963 shares of the company's stock worth $2,698,000 after purchasing an additional 9,769 shares in the last quarter. Xponance Inc. boosted its holdings in Vaxcyte by 13.4% during the fourth quarter. Xponance Inc. now owns 8,905 shares of the company's stock worth $729,000 after buying an additional 1,052 shares in the last quarter. Cibc World Markets Corp acquired a new stake in Vaxcyte during the fourth quarter valued at $951,000. Corient Private Wealth LLC raised its position in shares of Vaxcyte by 140.8% in the fourth quarter. Corient Private Wealth LLC now owns 5,404 shares of the company's stock worth $442,000 after acquiring an additional 3,160 shares during the period. Finally, Catalyst Funds Management Pty Ltd raised its position in shares of Vaxcyte by 1.7% in the fourth quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after acquiring an additional 300 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Vaxcyte Stock Down 1.9 %

Shares of NASDAQ PCVX traded down $1.31 during midday trading on Friday, hitting $69.46. The stock had a trading volume of 660,934 shares, compared to its average volume of 980,702. The stock has a 50 day simple moving average of $80.07 and a 200-day simple moving average of $92.37. The company has a market capitalization of $8.94 billion, a PE ratio of -15.10 and a beta of 1.02. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on PCVX shares. Needham & Company LLC restated a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, February 26th. The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective for the company. Finally, Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $147.50.

Insider Transactions at Vaxcyte

In other news, Director Teri Loxam sold 6,250 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the sale, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,250 shares of company stock valued at $3,840,018. Corporate insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.